Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma

BMC Cancer

Table 1 MMP-11 Levels and Clinical Characteristics

Clinical data	No. of Case (%)	MMP-11 level	P ^-value
		Mean ± SD (ng/ml)
NO. of patients	86
Gender
Male	60(69.8%)	45.76 ± 22.89	0.200
Female	26(30.2%)	38.79 ± 23.17
Age (yrs)
Median	51(50-56)
<65	63(73.3%)	43.40 ± 22.76	0.166
≥65	23(26.7%)	50.79 ± 21.96
Differentiation
G1, G2	23(26.7%)	48.56 ± 23.30	0.235
G3	63(73.3%)	41.86 ± 22.90
Histology
Intestinal type adenocarcinoma	54(62.8%)	44.22 ± 23.92
Mucinous carcinoma	20(23.2%)	45.89 ± 17.99	0.527
Signet-ring cell carcinoma	12(14.0%)	53.44 ± 23.80
ECOG
0-1	68(79.1%)	46.14 ± 21.40	0.610
2	18(20.9%)	43.33 ± 26.49
Disease stage
III c	26(30.2%)	43.22 ± 31.02	0.288
IV	60(69.8%)	48.45 ± 23.57
Metastasis site
Lymph node	35(40.7%) ^*#	52.55 ± 24.72
Peritoneum	21(24.4%) ^#	33.44 ± 14.46	0.006 (*0.029, ^#0.002)
Internal organs	30(34.9%) *	40.42 ± 22.74
Chemotherapy cycles	377
Median	6.00(3.00-12.00)
mTTP (m)
Median	6.00(5.29-6.71)
mOS (m)
Median	10.00(8.51-11.50)
Response
PR	38(44.2% )	46.85 ± 24.92	0.182
SD	22(25.6% )	37.34 ± 19.95
PD	26(30.2% )	48.97 ± 20.23

Abbreviations: PR, partial response; SD, stable disease; PD, progression of disease. Analysis of the difference between groups using analysis of variance (ANOVA). Where differences were identified, further analysis (between pairs of groups, with respective pairs for each molecule marked with *and *) was performed using Scheffe (95% confidence interval (CI))

ISSN: 1471-2407